SPOR data management services - high level changes

Similar documents
Pharmacovigilance: Information systems and services

EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables

Pharmacovigilance: Information systems and Services

EudraVigilance: Preparing for Change

ISO IDMP TF: Reports from subgroups. EU ISO IDMP Task Force meeting 12 June 2015

Scientific and Regulatory Evaluation Procedure Support [S-REPS] Pilot Update / System Preview

Pharmacovigilance in 2020: Boldly Shaping the Future An overview

EudraVigilance Registration Updates

New pharmacovigilance systems and services

Guidance on preparing for Brexit in the centralised procedure

Substance & Product Management Services (P&SMS) update

SPOR for VETERINARY. EU Network Data Board / SPOR Task Force 29, 30 June 1 July Presented by: Jos Olaerts Veterinary Division

Pharmacovigilance. An agency of the European Union

Pharmacovigilance and product data

Report from EMA industry survey on Brexit preparedness

Monthly statistics report: December 2017

Monthly statistics report: November 2016

Work plan for the CVMP Pharmacovigilance Working Party (PhVWP-V) 2018

Feedback on EudraVigilance & new functionalities

Pilot of MAH signal detection in EudraVigilance

Signal Management in the EU and future extended access to EudraVigilance for industry

EudraVigilance auditable requirement project

Overview of the Agency s role, activities and priorities for An agency of the European Union

Issues identified by stakeholders: follow-up from EMA s ATMP workshop

Engagement with stakeholders

EudraVigilance auditable requirement project: ADRreports.eu portal update

Redistribution of the UK centrally authorised product portfolio

The new EudraVigilance System Public Communications Plan for EMA and National Competent Authorities in the EEA

Publication of Risk Management Plan (RMP) summaries:

EU Portal and Database Update

Feedback to EUNDB on EU-SRS Business Case presentation at HMA II, Sofia

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports

Introduction to the Identification of Medicinal Products ( IDMP)

New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change

Explanatory note on fees payable to the European Medicines Agency

Clinical Trial Safety Reporting requirements

Conditional marketing authorisation

P&SMS Project Overview. An agency of the European Union

Update on EMA Brexit preparedness

Furthermore, the level of information and the subsequent assessment will vary on a case by case basis.

Implementation strategy of ICH Q3D guideline

Update on preparation for Signal Management

Draft document circulated to Committees drafting group members 20 October Committees consultation November Adoption January 2015

Comments from: Name of organisation or individual. Merck Sharp & Dohme (MSD)

Pharmacovigilance information for pharmaceutical companies

Medical Literature Monitoring

How to facilitate the cross-borders cross-domains identification of products (HL7 and IDMP) TSC Meeting, Sunday Q5, Baltimore (MD)

Applying for EU marketing authorisation. For medicinal products for human use. An agency of the European Union

PRIority MEdicines (PRIME)

Questions and answers on preparation, management and assessment of periodic safety update reports (PSURs)

EMA Working Groups on Committees' Operational Preparedness

Guidelines on good pharmacovigilance practices (GVP)

Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

We appreciate the opportunity to submit these comments for your consideration.

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

Stakeholders engagement

Brexit Guidance for Stakeholders Human and veterinary medicines

Pharmacovigilance information for pharmaceutical companies

Pharmacovigilance System Master file

Work plan for the GMP/GDP Inspectors Working Group for 2018

Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products

The role of patients at the EMA

EMA role in GMP Manufacturing and Quality Compliance

Explanatory note on fees payable to the European Medicines Agency

Title: Processing pharmacovigilance data in renewal procedures for centrally authorised medicinal products for veterinary use

Opinion/ Commission. Notification. Decision. Issued 2 / affected 3 amended on. 22/12/2016 n/a. 09/12/2016 n/a. 07/12/2016 SmPC

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

Considerations on regulatory aspects

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

ISO IDMP and the AIFA roadmap

Joint CVMP/CHMP Working group on the Application of the 3Rs in Regulatory Testing of Medical Products

Substance Subgroup Report to Task Force 10 March 2017

Publication of Risk Management Plan (RMP) summaries:

SME info day: The new clinical trial regulation

Marketing Authorisation Routes in the EU

Concept paper on the development of a guideline on quality and equivalence of topical products

Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 02/10/2018 SmPC, Labelling and PL. 30/04/2018 SmPC

Comments from: Leem (Les entreprises du Médicament)

E2B, Safety databases & Eudravigilance

International Generic Drug Regulators Programme (IGDRP) Information Sharing Pilot

Pre-accession product information linguistic review process (PALC III)

Commission. Product. Notification 1. Decision. Information issued on. Issued 2 / affected 3 amended on 30/01/2018 PL

Priority Medicines (PRIME) scheme

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

EMVO FMD Workshop Brussels 13. December 2016

PMS Data Quality PMS Subgroup meeting March Jeff Martin (SE MPA) & Martha Schei Hynne (NoMA) & ad-hoc NCA PMS group

Certification in Pharmaceutical Medicine and Clinical Research The vision of regulators

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 21/02/2018 n/a

NOAH represents the UK animal health industry. Promoting the development and use of safe, effective, quality medicines for the health and welfare of

European Medicines Agency decision

Work plan for the GMP/GDP Inspectors Working Group for 2017

Recent experience in scientific advice and marketing authorisations

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)

ENCePP Code of Conduct Revision 4

Implementation strategy of ICH Q3D guideline

Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation

EudraVigilance Veterinary

Standard operating procedure

Transcription:

6 July 2017 EMA/551661/2016 version 3 Information Management Division Table of contents 1. Introduction... 2 2. New solutions for access and use of SPOR data... 2 2.1. RMS backward compatibility... 2 2.2. RMS and OMS business services... 3 3. Data stewards... 3 4. Data content... 4 4.1. Referentials List release plan... 4 4.2. Content of the OMS dictionary... 4 5. RMS and OMS operating models... 5 5.1. Key features of the OMS and RMS operating models... 5 6. Data management... 5 7. EMA IT Service Desk... 6 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

1. Introduction RMS (Referentials Management Services) and OMS (Organisations Management Services) are the first two projects to be delivered as part of the phased implementation of SPOR and are key enablers of the implementation of ISO IDMP in the EU. The introduction of RMS and OMS will bring a number of key changes that can be classified as follows: New solutions providing access to SPOR data; Data stewards managing SPOR data; Data content to support ISO IDMP implementation; New RMS and OMS operating models; Ongoing data management activities; IT Service desk to support stakeholders. The impact of these changes will be experienced in different ways by Human and by Veterinary National Competent Authorities (NCAs) and by industry due to the variety in size, infrastructure and complexity of systems and processes within these organisations. NCAs and industry therefore need to understand what is changing centrally and then draw up implementation plans based on how they determine the changes will specifically impact their own organisation. At RMS and OMS go-live, submission processes will continue as before and there will be no immediate process changes for stakeholders. Some changes in the current submission processes are being explored and consultation is taking place with stakeholders on these. More information will be provided in due course to explain any applicable process changes and timings. 2. New solutions for access and use of SPOR data Stakeholders will be able to access and use the data within RMS and OMS via two methods: SPOR web interfaces reached via a portal. The SPOR web interfaces will provide a user-friendly (human to system) means of exploiting the business services of the web-based RMS and OMS applications; SPOR APIs (Application Programming Interface) a set of programming instructions and standards that organisations may choose to use to integrate with their local systems (system to system) in order to exploit the business services of the web-based RMS and OMS applications. The APIs can also be configured to manage automated data synchronisation. 2.1. RMS backward compatibility At RMS go-live, NCAs that currently use EUTCT (EU Telematics Controlled Terms) via the web user interface will find that they can still view Substances Lists but no longer view the Referentials Lists that were housed in EUTCT. However, those NCAs that currently use the EUTCT API will still be able to access the Referentials Lists that were in EUTCT due to the built-in backward compatibility. If users want to be able to view a complete set of Referentials Lists, i.e. those that include both Lists that were housed in EUTCT in addition to any new Lists, they will need to adopt the RMS API or RMS web user interface. EMA/551661/2016 Page 2/6

Table 1. RMS backward compatibility EUTCT web user interface Backwards compatible EUTCT API RMS web user interface RMS API Can only access Substances Lists Can access Substances Lists Cannot access Substances Lists Cannot access Substances Lists Unable to see Referentials Lists, which will have been migrated to RMS Can access Referentials Lists, which will have been migrated to RMS Can access all Referentials Lists in RMS (former EUTCT Lists plus new Lists) Can access all Referentials Lists in RMS (former EUTCT Lists plus new Lists) EUTCT is publicly available to NCAs, industry and any user for browsing but only NCAs can download the data and request changes to the data. 2.2. RMS and OMS business services RMS and OMS will offer a number of services and functionality, shown in the diagram below. All services will be available to all users with the exception of publishing documents which is only available to EMA and Term translations which are only available to NCAs. Figure 1. RMS and OMS business services 3. Data stewards Data stewards will be a specialised team of EMA staff that will manage the data (Referentials and Organisations initially). The overall objective of data stewards will be to apply consistent data quality EMA/551661/2016 Page 3/6

rules and standards. They will be responsible for validating access requests to SPOR data management services and for taking action on change requests for new/updated Referentials Lists/Terms and Organisations data. Data stewards will also be responsible to provide user support. 4. Data content The introduction of structured RMS and OMS data accompanied by unique IDs will support the implementation of ISO IDMP standards. 4.1. Referentials List release plan Referentials data will become available in RMS in phases over time. At go-live, the following Lists will be published: Lists from EUTCT (e.g. shelf life type, target species); New Lists to support OMS (e.g. party classification); New Lists to support PMS (e.g. material); Updated Lists for ISO 11239 (pharmaceutical dose form, routes of administration and packaging) and ISO 11240 (units of measurement).these Lists exist in EUTCT in a very flat structure and at go-live they will be structured with full ISO data elements. Referentials data will subsequently be expanded with Lists to support ISO standards for products and substances: ISO 11238 Referential data to support substance registration and ISO 11615 Referential data to support products. Further Lists can also be added in the future upon request. 4.2. Content of the OMS dictionary 1 The initial content of the dictionary at go-live included Regulatory Authorities/National Competent Authorities (NCAs). Data content will be incrementally expanded as part of maintenance work and the following data sets will be included: Data set 1: Marketing Authorisation Holders (MAHs): Human (H) + Veterinary (V) Centrally Authorised Products (CAPs) and Human (H) Nationally Authorised Products (NAPs); Marketing Authorisation Applicants (MAAs): (H+V) CAPs; Maximum Residue Limit (MRL) applicants (Veterinary). Data set 2: Sponsors (H) CAPs and NAPs. Data set 3: Manufacturers (H+V) CAPs. Data set 4: Manufacturers (H+V) NAPs. EMA will communicate in advance to stakeholders about the timing of the release of new Organisation data in the dictionary and specify when industry can start submitting change requests for the Organisation data that has been added. 1 Section 4.2 was updated to reflected current OMS data release plan EMA/551661/2016 Page 4/6

Additional Organisation data will be published in the future and the prioritisation of its inclusion in the dictionary will be defined at a later stage: Veterinary MAHs for NAPs; Contract Research Organisations (CROs); Clinical trials sites; Academia; Hospitals; Wholesale distributers; MAA/MAH and manufacturers in the context of herbal and homeopathic medicinal products or compassionate use medicinal products; QPPV (Qualified Person for Pharmacovigilance). 5. RMS and OMS operating models EMA will act as a broker by making available a single source of centrally-provided master data and accompanying data management services to NCAs, EMA itself, industry and other external stakeholders. These data management services will be supported by standard processes, also referred to as operating models, which will enable a more efficient and consistent way of managing data. 5.1. Key features of the OMS and RMS operating models Common process for industry to pre-register/update Organisations and Referentials data before submitting regulatory applications; Establishment of a centralised dictionary of Organisations and Lists of Referentials to be used as a reference for, and in support of, EU regulatory activities; Data validated by EMA data stewards and made available in a structured format in line with ISO/EU standards; Validated, re-usable, quality data; A system to generate and maintain Organisation IDs and Referential IDs for use in regulatory submissions from across EMA, industry and NCAs; Common API interface for exchange of Referentials and Organisations data. 6. Data management In order to reflect changes/updates in SPOR data in their local systems, NCAs and industry may need to enhance their local data to align with ISO/EU data formats within RMS and OMS in the following ways: Data transformation change the data structure, e.g. split data fields; Data enrichment complete the set of data, e.g. add a new field such as post code; Data mapping where there is a need to maintain local data, e.g. local controlled vocabularies, mapping may be required between local data and central SPOR data to produce outputs in line with ISO/EU terminology and formats. EMA/551661/2016 Page 5/6

NCAs and industry will also need to synchronise or maintain mappings in their local systems with RMS and OMS on an ongoing basis in order to ensure they are using the correct data in regulatory submissions. They may choose to make use of the RMS and OMS web APIs to support them in automating the synchronisation of data or in the maintenance of the mapping of the data. 7. EMA IT Service Desk The EMA IT Service Desk will provide technical support for SPOR data management services for all stakeholders. More information will be provided nearer to RMS and OMS go-live, such as contact details and the specific help that will be on offer. EMA/551661/2016 Page 6/6